Filgrastim-Sndz (ZARXIO)
Leukocyte Growth Factor class · 0 generic manufacturers · 0 ANDAs filed at FDA.
$69.5M in CY2024 Part D spend35K claims · 14K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Filgrastim-Sndz used for?
Filgrastim-Sndz is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Filgrastim-Sndz?
No. Filgrastim-Sndz is brand-only with no generic equivalents currently in market.
How much does my plan pay for Filgrastim-Sndz?
Across 329 Part D plans, Filgrastim-Sndz averages $532.53/unit (NADAC). Lowest available: $531.65/unit. Highest in distribution: $533.41/unit.
Is Filgrastim-Sndz on the FDA shortage list?
No. Filgrastim-Sndz is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.